Genistin: A Novel Estrogen Analogue Targeting ERβ to Alleviate Thrombocytopenia

Int J Biol Sci. 2024 Mar 25;20(6):2236-2260. doi: 10.7150/ijbs.90483. eCollection 2024.

Abstract

Thrombocytopenia, a prevalent hematologic challenge, correlates directly with the mortality of numerous ailments. Current therapeutic avenues for thrombocytopenia are not without limitations. Here, we identify genistin, an estrogen analogue, as a promising candidate for thrombocytopenia intervention, discovered through AI-driven compound library screening. While estrogen's involvement in diverse biological processes is recognized, its role in thrombopoiesis remains underexplored. Our findings elucidate genistin's ability to enhance megakaryocyte differentiation, thereby augmenting platelet formation and production. In vivo assessments further underscore genistin's remedial potential against radiation-induced thrombocytopenia. Mechanistically, genistin's efficacy is attributed to its direct interaction with estrogen receptor β (ERβ), with subsequent activation of both ERK1/2 and the Akt signaling pathways membrane ERβ. Collectively, our study positions genistin as a prospective therapeutic strategy for thrombocytopenia, shedding light on novel interplays between platelet production and ERβ.

Keywords: ERβ; Estrogen Analogue; Genistin; thrombocytopenia.

MeSH terms

  • Estrogen Receptor beta / genetics
  • Humans
  • Isoflavones*
  • Small Molecule Libraries
  • Thrombocytopenia* / drug therapy

Substances

  • Estrogen Receptor beta
  • genistin
  • Isoflavones
  • Small Molecule Libraries